ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG VÀ KẾT QUẢ HÓA – XẠ TRỊ ĐỒNG THỜI SAU MỔ UNG THƯ TRỰC TRÀNG TẠI BỆNH VIỆN UNG BƯỚU THÀNH PHỐ CẦN THƠ NĂM 2020-2022

Abstract

  Background: Rectal cancer is a curable disease if detected at an early stage. In the treatment of rectal cancer, surgery is still the basic radical treatment method, but when the disease is at an advanced stage, surgery alone will face many limitations. To improve the outcome of these patients, concurrent chemoradiotherapy after surgery has been proposed. Objectives: To survey some clinical and subclinical characteristics, to evaluate the results and find out some factors related to the treatment results of chemoradiotherapy simultaneously after surgery in patients with rectal cancer from May 2020 to March 2022. Materials and methods: All rectal cancer patients had surgery from 4-6 weeks,did not receive preoperative treatment, received chemotherapy. This was a descriptive study. Results: Sex: male/female=1.13. Most of the patients studied were over 40 years old (96.7%). There were 29% lower third rectal cancer; 24.2% middle third rectal cancer; 27.4% upper third rectal cancer and 19.4% rectosigmoid junction cancer. The recorded surgical methods were included: low anterior resection (50%), anterior resection (30.6%), Miles (17.7%), ultra-low anterior resection (1.6%). The estimated 2 year disease free survival was: 83.9 ± 8.2%. Common site of recurrence was: liver (60%). The estimated 2 year overall survival was: 94.5 ± 3.1%. The analysis showed a statistically significant difference between diabetes mellitus, CEA levels, tumor macroscopicity, disease stage, number of metastatic nodes and disease – free survival. Conclusion: Simultaneous chemoradiotherapy after surgery helps to control well locally, reduces local recurrence rate, prolongs disease – free survival and overall survival.